Chemotherapy of Brain Metastases from Lung Carcinoma: A Controlled Randomized Study

Author:

Ushio Yukitaka1,Arita Norio2,Hayakawa Toru2,Mogami Heitaro2,Hasegawa Hiroshi3,Bitoh Shoji3,Oku Yuzuru4,Ikeda Hiroya5,Kanai Nobuhiro6,Kanoh Mitsuaki7,Akagi Katsuhito8,Nakagawa Hidemitsu9

Affiliation:

1. Department of Neurosurgery, Kumamoto University Medical School Osaka, Japan

2. Departments of Neurosurgery, Osaka University Medical School Osaka, Japan

3. Osaka Koseinenkin Hospital Osaka, Japan

4. Kansai Rosai Hospital Osaka, Japan

5. Itami City Hospital Osaka, Japan

6. Toyonaka City Hospital Osaka, Japan

7. Osaka Rosai Hospital Osaka, Japan

8. Osaka National Hospital Osaka, Japan

9. Hospital for Adult Diseases, Osaka, Japan

Abstract

Abstract A controlled randomized study was carried out to evaluate the effects of chemotherapy in patients with brain metastases from lung carcinoma. One hundred patients were randomly divided into three groups at the time of diagnosis or after surgery for metastases. Group A received radiotherapy alone; Group B received radiotherapy and chloroethylnitrosoureas (methyl-CCNU, 100-120 mg/m2, or ACNU 80-100 mg/m2, every 6-8 weeks), and Group C received radiotherapy and a combination of chloroethylnitrosoureas and tegafur (300 mg/m2. daily). Of the 100 patients, 88 could be evaluated. The reduction rates of the tumors of the patients in whom tumor was not surgically removed or not totally removed were compared. Complete resolution of the tumor was noted in 29, 69, and 63% of the patients in Groups A, B, and C, respectively, Tumor regression of ⩾50% was seen in 36, 69. and 74% of the patients in Groups A, B, and C, respectively. The difference in the response rates of Groups A and C was statistically signficiant (P<0.05). Median survival after the start of treatment for brain metastasis was 27, 30.5, and 29 weeks in Groups A, B, and C, respectively. There was 1 long-term survivor (more than 5 years) in Group A, 3 in Group B, and 1 in Group C. The main cause of death was deterioration attributable to the primary lesion or systemic metastasis, and no statistical difference was noted in survival time among the groups. Our results indicate that combination chemotherapy with chloroethylnitrosoureas and tegafur has an additive effect on radiotherapy in reducing or eliminating brain metastases from lung carcinoma, and that brain metastasis is well controlled by multidisciplinary treatment including chemotherapy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Clinical Neurology,Surgery

Cited by 95 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Pathology and treatment of primary and metastatic brain tumors;Neuropsychological and Psychosocial Foundations of Neuro-Oncology;2024

2. Overview of pathology and treatment of metastatic brain tumors;Handbook of Neuro-Oncology Neuroimaging;2022

3. Intracranial metastases;Neurological Complications of Systemic Cancer and Antineoplastic Therapy;2022

4. Treatment Patterns and Survival Outcomes of Non-Small Cell Lung Cancer Patients Initially Diagnosed With Brain Metastases in Real-World Clinical Practice;Frontiers in Oncology;2020-10-09

5. Dose Tolerances in Brain Metastasis Management;Radiotherapy in Managing Brain Metastases;2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3